A worker scans the barcode on the Avifavir antiviral drug approved to treat patients suffering from the coronavirus, at a storage facility at the unknown location, Russia. The Russian Direct Investment Fund (RDIF) and the ChemRar pharmaceutical company said on June 11 they started delivering Avifavir medication against COVID-19 to hospitals across the country. Avifavir, created on the basis of Favipiravir, is one of the two drugs for COVID-19 treatment registered globally. In early June, the Russian Health Ministry said that the medication had proven 90 percent efficient during trials.

10.06.2020#6262001

Workers move boxes containing the Avifavir antiviral drug approved to treat patients suffering from the coronavirus, at a storage facility at the unknown location, Russia. The Russian Direct Investment Fund (RDIF) and the ChemRar pharmaceutical company said on June 11 they started delivering Avifavir medication against COVID-19 to hospitals across the country. Avifavir, created on the basis of Favipiravir, is one of the two drugs for COVID-19 treatment registered globally. In early June, the Russian Health Ministry said that the medication had proven 90 percent efficient during trials.

10.06.2020#6262000

Boxes containing the Avifavir antiviral drug approved to treat patients suffering from the coronavirus, are pictured at the unknown location, Russia. The Russian Direct Investment Fund (RDIF) and the ChemRar pharmaceutical company said on June 11 they started delivering Avifavir medication against COVID-19 to hospitals across the country. Avifavir, created on the basis of Favipiravir, is one of the two drugs for COVID-19 treatment registered globally. In early June, the Russian Health Ministry said that the medication had proven 90 percent efficient during trials.

10.06.2020#6261992

Boxes containing the Avifavir antiviral drug approved to treat patients suffering from the coronavirus, are pictured at the unknown location, Russia. The Russian Direct Investment Fund (RDIF) and the ChemRar pharmaceutical company said on June 11 they started delivering Avifavir medication against COVID-19 to hospitals across the country. Avifavir, created on the basis of Favipiravir, is one of the two drugs for COVID-19 treatment registered globally. In early June, the Russian Health Ministry said that the medication had proven 90 percent efficient during trials.

10.06.2020#6261985

The Avifavir antiviral drug approved to treat patients suffering from the coronavirus, is displayed at the unknown location, Russia. The Russian Direct Investment Fund (RDIF) and the ChemRar pharmaceutical company said on June 11 they started delivering Avifavir medication against COVID-19 to hospitals across the country. Avifavir, created on the basis of Favipiravir, is one of the two drugs for COVID-19 treatment registered globally. In early June, the Russian Health Ministry said that the medication had proven 90 percent efficient during trials.

10.06.2020#6261983

The Avifavir antiviral drug approved to treat patients suffering from the coronavirus, is displayed at the unknown location, Russia. The Russian Direct Investment Fund (RDIF) and the ChemRar pharmaceutical company said on June 11 they started delivering Avifavir medication against COVID-19 to hospitals across the country. Avifavir, created on the basis of Favipiravir, is one of the two drugs for COVID-19 treatment registered globally. In early June, the Russian Health Ministry said that the medication had proven 90 percent efficient during trials.

10.06.2020#6261982

A woman demonstrates the Avifavir antiviral drug approved to treat patients suffering from the coronavirus, at the unknown location, Russia. The Russian Direct Investment Fund (RDIF) and the ChemRar pharmaceutical company said on June 11 they started delivering Avifavir medication against COVID-19 to hospitals across the country. Avifavir, created on the basis of Favipiravir, is one of the two drugs for COVID-19 treatment registered globally. In early June, the Russian Health Ministry said that the medication had proven 90 percent efficient during trials.

10.06.2020#6261981

Pharmacy manager Olga Panina demonstrates the Avifavir antiviral drug approved to treat patients suffering from the coronavirus, at the unknown location, Russia. The Russian Direct Investment Fund (RDIF) and the ChemRar pharmaceutical company said on June 11 they started delivering Avifavir medication against COVID-19 to hospitals across the country. Avifavir, created on the basis of Favipiravir, is one of the two drugs for COVID-19 treatment registered globally. In early June, the Russian Health Ministry said that the medication had proven 90 percent efficient during trials.

10.06.2020#6261979

Pharmacy manager Olga Panina demonstrates the Avifavir antiviral drug approved to treat patients suffering from the coronavirus, at the unknown location, Russia. The Russian Direct Investment Fund (RDIF) and the ChemRar pharmaceutical company said on June 11 they started delivering Avifavir medication against COVID-19 to hospitals across the country. Avifavir, created on the basis of Favipiravir, is one of the two drugs for COVID-19 treatment registered globally. In early June, the Russian Health Ministry said that the medication had proven 90 percent efficient during trials.

10.06.2020#6261978

Pharmacy manager Olga Panina demonstrates the Avifavir antiviral drug approved to treat patients suffering from the coronavirus, at the unknown location, Russia. The Russian Direct Investment Fund (RDIF) and the ChemRar pharmaceutical company said on June 11 they started delivering Avifavir medication against COVID-19 to hospitals across the country. Avifavir, created on the basis of Favipiravir, is one of the two drugs for COVID-19 treatment registered globally. In early June, the Russian Health Ministry said that the medication had proven 90 percent efficient during trials.

10.06.2020#6261977

Pharmacy manager Olga Panina demonstrates the Avifavir antiviral drug approved to treat patients suffering from the coronavirus, at the unknown location, Russia. The Russian Direct Investment Fund (RDIF) and the ChemRar pharmaceutical company said on June 11 they started delivering Avifavir medication against COVID-19 to hospitals across the country. Avifavir, created on the basis of Favipiravir, is one of the two drugs for COVID-19 treatment registered globally. In early June, the Russian Health Ministry said that the medication had proven 90 percent efficient during trials.

10.06.2020#6261976

Pharmacy manager Olga Panina demonstrates the Avifavir antiviral drug approved to treat patients suffering from the coronavirus, at the unknown location, Russia. The Russian Direct Investment Fund (RDIF) and the ChemRar pharmaceutical company said on June 11 they started delivering Avifavir medication against COVID-19 to hospitals across the country. Avifavir, created on the basis of Favipiravir, is one of the two drugs for COVID-19 treatment registered globally. In early June, the Russian Health Ministry said that the medication had proven 90 percent efficient during trials.

10.06.2020#6261974

An employee demonstrates the production process of antiviral drug Favipiravir at the enterprise of ChemRar Group in Khimki, outside Moscow, Russia. Russia is set to test Favipiravir, an off-patent drug originally owned by Japanese drug maker Fujifilm Toyama Chemical, as a treatment for coronavirus patients as it holds potential against RNA viruses, one of which is Covid-19.

30.04.2020#6232018

An employee demonstrates the production process of antiviral drug Favipiravir at the enterprise of ChemRar Group in Khimki, outside Moscow, Russia. Russia is set to test Favipiravir, an off-patent drug originally owned by Japanese drug maker Fujifilm Toyama Chemical, as a treatment for coronavirus patients as it holds potential against RNA viruses, one of which is Covid-19.

30.04.2020#6232017

An employee demonstrates the production process of antiviral drug Favipiravir at the enterprise of ChemRar Group in Khimki, outside Moscow, Russia. Russia is set to test Favipiravir, an off-patent drug originally owned by Japanese drug maker Fujifilm Toyama Chemical, as a treatment for coronavirus patients as it holds potential against RNA viruses, one of which is Covid-19.

30.04.2020#6232016

Tablets are pictured during a demonstration of the production process of antiviral drug Favipiravir at the enterprise of ChemRar Group in Khimki, outside Moscow, Russia. Russia is set to test Favipiravir, an off-patent drug originally owned by Japanese drug maker Fujifilm Toyama Chemical, as a treatment for coronavirus patients as it holds potential against RNA viruses, one of which is Covid-19.

30.04.2020#6232015

Employees demonstrate the production process of antiviral drug Favipiravir at the enterprise of ChemRar Group in Khimki, outside Moscow, Russia. Russia is set to test Favipiravir, an off-patent drug originally owned by Japanese drug maker Fujifilm Toyama Chemical, as a treatment for coronavirus patients as it holds potential against RNA viruses, one of which is Covid-19.

30.04.2020#6232013

An employee demonstrates the production process of antiviral drug Favipiravir at the enterprise of ChemRar Group in Khimki, outside Moscow, Russia. Russia is set to test Favipiravir, an off-patent drug originally owned by Japanese drug maker Fujifilm Toyama Chemical, as a treatment for coronavirus patients as it holds potential against RNA viruses, one of which is Covid-19.

30.04.2020#6232014

Employees demonstrate the production process of antiviral drug Favipiravir at the enterprise of ChemRar Group in Khimki, outside Moscow, Russia. Russia is set to test Favipiravir, an off-patent drug originally owned by Japanese drug maker Fujifilm Toyama Chemical, as a treatment for coronavirus patients as it holds potential against RNA viruses, one of which is Covid-19.

30.04.2020#6232012

An employee demonstrates the production process of antiviral drug Favipiravir at the enterprise of ChemRar Group in Khimki, outside Moscow, Russia. Russia is set to test Favipiravir, an off-patent drug originally owned by Japanese drug maker Fujifilm Toyama Chemical, as a treatment for coronavirus patients as it holds potential against RNA viruses, one of which is Covid-19.

30.04.2020#6232009

An employee demonstrates the production process of antiviral drug Favipiravir at the enterprise of ChemRar Group in Khimki, outside Moscow, Russia. Russia is set to test Favipiravir, an off-patent drug originally owned by Japanese drug maker Fujifilm Toyama Chemical, as a treatment for coronavirus patients as it holds potential against RNA viruses, one of which is Covid-19.

30.04.2020#6232008

An employee demonstrates a tablet of antiviral drug Favipiravir at the enterprise of ChemRar Group in Khimki, outside Moscow, Russia. Russia is set to test Favipiravir, an off-patent drug originally owned by Japanese drug maker Fujifilm Toyama Chemical, as a treatment for coronavirus patients as it holds potential against RNA viruses, one of which is Covid-19.

30.04.2020#6232007

An employee demonstrates the production process of antiviral drug Favipiravir at the enterprise of ChemRar Group in Khimki, outside Moscow, Russia. Russia is set to test Favipiravir, an off-patent drug originally owned by Japanese drug maker Fujifilm Toyama Chemical, as a treatment for coronavirus patients as it holds potential against RNA viruses, one of which is Covid-19.

30.04.2020#6232006

An employee demonstrates a tablet of antiviral drug Favipiravir at the enterprise of ChemRar Group in Khimki, outside Moscow, Russia. Russia is set to test Favipiravir, an off-patent drug originally owned by Japanese drug maker Fujifilm Toyama Chemical, as a treatment for coronavirus patients as it holds potential against RNA viruses, one of which is Covid-19.

30.04.2020#6232005